证券代码：002737 证券简称：葵花药业 公告编号：2025-057 葵花药业集团股份有限公司 关于盐酸非索非那定口服混悬液获得药品注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 葵花药业集团股份有限公司（以下简称"公司"或"本公司"）子公司于近 日收到国家药品监督管理局下发的关于盐酸非索非那定口服混悬液获批注册的 药品注册证书，现将有关情况公告如下： 一、 药物的基本情况 1、药品通用名称：盐酸非索非那定口服混悬液 2、主要成份：盐酸非索非那定 6、处方药/非处方药：处方药 7、药品批准文号：国药准字 H20255183 8、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明 书、标签及生产工艺照所附执行。药品生产企业应当符合药品生产质量管理规范 要求方可生产销售。 9、适应症： 季节性过敏性鼻炎: 3、申请事项：药品注册(境内生产) 4、规格：120ml:0.72g 5、注册分类：化学药品 3 类 二、风险提示 盐酸非索非那定口服混悬液应用于抗过敏领域，该 ...

Core Viewpoint - The company, KuaHua Pharmaceutical, reported a significant decline in net profit and revenue in the first half of 2025, but showed signs of stabilization in Q2, with a focus on channel inventory management and strategic reforms to prepare for future growth [2][3][10]. Financial Performance - In the first half of 2025, KuaHua Pharmaceutical achieved a net profit of 81.31 million yuan and a net profit of 48.19 million yuan after deducting non-recurring items, both showing a significant decline compared to the same period last year [2]. - The pharmaceutical manufacturing industry experienced a revenue decline of 1.2% year-on-year, with total profits down 2.8% [2]. Inventory Management - The company actively managed channel inventory, leading to a reduction in inventory pressure despite short-term impacts on revenue and profit [3][4]. - The inventory management strategy has shown positive results, with channel inventory returning to a healthier state, indicating potential for revenue growth as demand recovers [4]. Product Strategy - KuaHua Pharmaceutical is focusing on the "one elderly, one child, one woman" strategy, enhancing its product offerings in these core areas [5][7]. - New product launches, such as ibuprofen suspension for children and polyethylene glycol for adults, are aimed at filling market gaps and enhancing competitiveness [7]. Market Opportunities - The company is expanding into the health sector and optimizing its channel structure to diversify growth avenues and reduce reliance on OTC drug sales [8]. - External factors, such as childcare subsidies and stricter drug regulations, are expected to boost demand for children's medications and strengthen the competitive position of leading companies like KuaHua Pharmaceutical [9][10]. Future Outlook - The combination of internal improvements and favorable external conditions suggests that KuaHua Pharmaceutical is well-positioned for a recovery in performance, with potential for accelerated growth as the industry stabilizes [10].

Core Viewpoint - The company, Kew Flower Pharmaceutical, reported a revenue of 1.31 billion yuan and a net profit of 81.31 million yuan for the first half of 2025, indicating a strategic shift towards health management and quality-focused pharmaceutical services in response to industry changes [1][2]. Group 1: Financial Performance - Kew Flower Pharmaceutical achieved a revenue of 1.31 billion yuan and a net profit of 81.31 million yuan in the first half of 2025 [1]. - The company has seen a recovery in downstream commercial inventory, returning to normal levels by the end of July 2025 after a year of strategic adjustments [2]. Group 2: Strategic Adjustments - The company is focusing on the "elderly, children, and women" sectors, implementing differentiated competition strategies and obtaining drug registration certificates for key products like polyethylene glycol 3350 and ibuprofen suspension [1]. - Kew Flower Pharmaceutical is actively developing new products, with six varieties currently under review for market approval [1]. Group 3: R&D and Brand Development - The company is advancing its research in probiotics and health products, with ongoing projects for developing proprietary strains and functional studies [1]. - The brand value of Kew Flower Pharmaceutical's "Kew Flower" and "Little Kew Flower" has reached 36.578 billion yuan, highlighting the strength of its dual-brand strategy [2].

Group 1 - The company, Kew Flower Pharmaceutical, announced on August 28 that its fifth board meeting was held via communication on August 27, 2025 [1] - The meeting reviewed the proposal regarding the full and summary report for the company's 2025 semi-annual report [1] Group 2 - The news highlights a significant medical advancement with the world's first successful transplantation of gene-edited pig lungs into a human [1] - The article includes a dialogue with key participants discussing the timeline for clinical application of this breakthrough [1]

葵花药业集团股份有限公司 2025 年半年度非经营性资金占用及其他关联资金往来情况汇总表 汇总表第 1页 单位：万元 | | | | 占用方与上市公 | | 2025 年期初占 | | 2025 年半年度占 | 2025 年半年度占用 | 2025 | 年半年度度偿 | 2025 年半年度期 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | | 资金占用方名称 | 司的关联关系 | 上市公司核算的会计科目 | 用资金余额 | | 用累计发生金额 （不含利息） | 资金的利息(如有) | | 还累计发生金额 | 末占用资金余额 | 占用形成原因 | 占用性质 | | 控股股东、实际控制 | | | | | | | | | | | | | | | 人及其附属企业 | | | | | | | | | | | | | | | 小计 | | - | - | - | | | | | | | | - | - | | 前控股股东、实际控 | | | | | | | | ...

葵花药业集团股份有限公司 2025 年半年度财务报告 葵花药业集团股份有限公司 合并资产负债表 2025年6月30日 （除特别注明外，金额单位均为人民币元） | 项 目 | 附 注 | 期末余额 | 期初余额 | | --- | --- | --- | --- | | 流动资产： | | | | | 货币资金 | 五、1 | 1,441,570,709.72 | 1,040,228,908.13 | | 交易性金融资产 | 五、2 | 1,200,000,000.00 | 1,258,256,600.00 | | 衍生金融资产 | | | | | 应收票据 | 五、3 | 34,060,738.63 | 7,449,631.47 | | 应收账款 | 五、4 | 208,265,660.36 | 207,740,418.62 | | 应收款项融资 | 五、5 | 97,165,087.91 | 369,744,164.58 | | 预付款项 | 五、7 | 71,820,979.81 | 56,259,736.01 | | 其他应收款 | 五、6 | 15,013,677.69 | 14,949,966.36 ...

证券代码：002737 证券简称：葵花药业 公告编号：2025-054 葵花药业集团股份有限公司 第五届监事会第五次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、监事会会议召开情况 葵花药业集团股份有限公司（以下简称"公司"或"本公司"）第五届监事 会第五次会议于 2025 年 8 月 27 日以通讯方式召开。本次会议由公司监事会主席 何岩女士召集，会议通知及议案于 2025 年 8 月 17 日通过电子邮件形式发出。 会议应参加表决监事三人，实际参加表决监事三人，本次会议召集和召开程 序符合《公司法》及《公司章程》之规定，会议决议合法有效。 二、监事会会议审议情况 1、审议通过《关于公司 2025 年半年度报告全文及摘要的议案》 经审核，监事会认为，公司董事会编制和审议公司 2025 年半年度报告全文 及摘要的程序符合法律、行政法规及中国证监会的规定，报告内容真实、准确、 完整地反映了上市公司的实际情况，不存在任何虚假记载、误导性陈述或者重大 遗漏。 表决结果：同意 3 票，反对 0 票，弃权 0 票，通过。 2、审议通过《公司 2025 ...

一、董事会会议召开情况 证券代码：002737 证券简称：葵花药业 公告编号：2025-053 葵花药业集团股份有限公司 第五届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 《公司 2025 年半年度非经营性资金占用及其他关联资金往来情况汇总表》 披露于本公司指定信息披露媒体巨潮资讯网（www.cninfo.com.cn ）。 表决结果：同意 9 票，反对 0 票，弃权 0 票，通过。 专门委员会审议情况：本议案提交董事会审议前业经公司第五届董事会审计 委员会 2025 年第三次会议、公司独立董事 2025 年第二次专门会议审议通过。 葵花药业集团股份有限公司（以下简称"公司"或"本公司"）第五届董事 会第十次会议于 2025 年 8 月 27 日上午 9 时 30 分以通讯方式召开。会议由公司 董事长关玉秀女士召集，会议通知及议案于 2025 年 8 月 17 日通过电子邮件形式 发出。会议应参加表决董事 9 人，实际参加表决董事 9 人。 本次会议召集、召开程序符合《公司法》及相关法律法规以及《公司章程》 之规定，会议决议合法有 ...

Core Viewpoint - The company reported a significant decline in both revenue and net profit for the first half of the year, indicating potential challenges in its financial performance [1] Financial Performance - The company achieved a revenue of 1.31 billion yuan in the first half of the year, representing a year-on-year decrease of 48.17% [1] - The net profit attributable to shareholders was 81.31 million yuan, down 83.28% from 486 million yuan in the same period last year [1] - The basic earnings per share were reported at 0.14 yuan [1]

Core Viewpoint - The company reported a significant decline in both revenue and net profit for the first half of 2025, indicating potential challenges in its operational performance [1]. Financial Performance - The company's operating revenue for the first half of 2025 was 1.31 billion yuan, representing a year-on-year decrease of 48.17% [1]. - The net profit for the same period was 81.31 million yuan, reflecting a year-on-year decline of 83.28% [1].